NewAmsterdam Pharma Company N.V. (SPAC merger) to go public via business combination with Frazier Lifesciences Acquisition Corporation

Siegfried Holding AG to Acquire Noramco, Extractas Biosciences and Purisys from SK Capital Partners

January 27, 2026

Healthcare Services

Affiliates of funds advised by SK Capital Partners have entered into an agreement to sell Noramco, Extractas Biosciences, and Purisys of the Noramco Group to Siegfried Holding AG. The deal is subject to customary closing conditions and regulatory approvals, with SK Capital retaining ownership of Halo Pharmaceuticals after closing.

Voyager Acquisition Corp and VERAXA Biotech Announce Form F-4 Filing for Proposed Business Combination

July 17, 2025

Healthcare Services

VERAXA Biotech AG and Voyager Acquisition Corp. (a SPAC) have filed a Form F-4 registration statement with the SEC in connection with their proposed business combination announced in April 2025. Under the terms, VERAXA shareholders are expected to roll over 100% of their equity and receive approximately 130 million ordinary shares of the combined company, with the deal expected to close in Q4 2025.

NLS Pharmaceutics to Merge with Kadimastem to Form NewcelX

June 27, 2025

Biotechnology

NLS Pharmaceutics (NASDAQ: NLSP) and Kadimastem (TASE: KDST) are progressing with their proposed merger, which would combine their CNS biopharmaceutical and off-the-shelf allogeneic cell therapy pipelines into a Nasdaq-traded company named NewcelX. The transaction is supported by financing actions (including equity financings and a $25 million committed equity facility) and shareholder approvals, with the companies targeting completion in early Q3 2025.

Abra Financial Holdings to Go Public via SPAC Merger with New Providence Acquisition Corp. III

March 16, 2026

Financial Services

Abra Financial Holdings announced plans to become a publicly traded company through a business combination with special purpose acquisition company New Providence Acquisition Corp. III. The deal values Abra at a $750 million pre-money equity valuation and is expected to provide growth capital, with shares expected to trade on Nasdaq under ticker ABRX after closing.

NLS Pharmaceutics and Kadimastem Complete Merger to Form NewcelX Ltd

October 30, 2025

Biotechnology

Swiss-based NLS Pharmaceutics Ltd. merged with clinical-stage cell therapy company Kadimastem Ltd. to create a combined Nasdaq-listed biotechnology company named NewcelX Ltd. The merger closed effective October 30, 2025, with the new company beginning trading on the Nasdaq Capital Market on October 31, 2025 under ticker “NCEL.”

AmerisourceBergen Acquires PharmaLex for €1.28 Billion

December 31, 2022

Healthcare Services

AmerisourceBergen Corporation signed a definitive agreement to acquire PharmaLex Holding GmbH for €1.28 billion in cash. The deal is intended to expand AmerisourceBergen’s global biopharma services platform by adding PharmaLex’s tech-enabled, regulatory-focused life sciences expertise.